vincamine has been researched along with Lung Injury, Acute in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Durga Veera Hanuman, D; Gadige, A; Khurana, A; Kumar Banothu, A; Kumar Bharani, K; Mahesh Kumar, J; Mekala, L; Neeradi, D; Patangrao Renushe, A | 1 |
1 other study(ies) available for vincamine and Lung Injury, Acute
| Article | Year |
|---|---|
Vincamine, an active constituent of Vinca rosea ameliorates experimentally induced acute lung injury in Swiss albino mice through modulation of Nrf-2/NF-κB signaling cascade.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Catharanthus; COVID-19; Cytokines; Inflammation; Interleukin-10; Lipopolysaccharides; Lung; Mice; NF-kappa B; Respiratory Distress Syndrome; Tumor Necrosis Factor-alpha; Vincamine | 2022 |